HST Global Intends to Focus on Development of Health and Wellness Centers,
Immunotherapy Treatments and Cognitive Function Technologies
HAMPTON, Va.--(Business Wire)--
HST Global, Inc. (OTCBB:HSTC) today announced the termination of its Letter of
Intent Agreement to purchase Bryomed International, Inc. The Company looks
forward to maintaining the relationship between the parties and will continue to
pursue a vendor agreement as Bryomed continues the registration process of its
products with the FDA. HST will also discontinue its efforts to purchase the
worldwide rights for the manufacturing and distribution of Salicinium.
Ron Howell, CEO/President, stated, "With the current economic climate, we will
dedicate all of our company resources to the development and expansion of our
distribution through our Health and Wellness Centers. Under the guidance of Dr.
Forsythe we will continue developing appropriate protocols to address life
threatening diseases. At the same time, we expect to accelerate the opening of
our proto-type Center in Las Vegas. In addition, we will mature the expansion
and development of our "all natural" nutritional products designed to address
wellness challenges and provide preventative maintenance for overall health.
This will allow us to concentrate on products that we control from formulation
through to consumer application as well as integrating the educational process
necessary to help patients understand the underlying need for good nutrition in
achieving and maintaining optimum health."
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that
is developing and or acquiring a network of Wellness Centers worldwide that are
primarily focused on the immunotherapy and alternative treatment of late stage
cancer. In addition, the company intends to acquire innovative products for the
treatment of late stage cancer. In this regard, the company primarily focuses on
immunotherapy and alternative product candidates that are undergoing or have
already completed significant clinical testing for the treatment of late stage
cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in
this release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to time
in the Company's periodic reports filed with the Securities and Exchange
Commission.
HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com
Copyright Business Wire 2009
